Crinetics Pharmaceuticals Inc (CRNX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Crinetics Pharmaceuticals Inc (CRNX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8089
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Crinetics Pharmaceuticals Inc (Crinetics) is a developer of novel therapeutics targeting peptide hormone receptors for the treatment of rare endocrine disorders and endocrine-related cancers. The company’s products include neuropeptides and their receptors, orally-available somatostatin agonists, and orally available kisspeptin antagonists. Its neuropeptides controls aspects of human development, physiology and oncogenesis. Crinetics provides somatostatin agonists for the treatment of pancreatic neuroendocrine tumors, carcinoid tumors, GH secreting adenomas, diabetic retinopathy, graves ophthalmopathy, chronic pain, epilepsy, and dementia; and kisspeptin antagonists for the treatment of endometriosis, uterine fibroids, and PCOS. The company provides endocrine drug discovery and development through collaboration with healthcare and research institutes. Crinetics is headquartered in San Diego, California, the US.

Crinetics Pharmaceuticals Inc (CRNX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Crinetics Pharma Raises USD63.5 Million in Series B Financing 10
Crinetics Pharma Raises USD40 Million in Series A Financing Round 12
Equity Offering 13
Crinetics Pharma Raises USD117.3 Million in IPO of Shares 13
Crinetics Pharmaceuticals Inc – Key Competitors 14
Crinetics Pharmaceuticals Inc – Key Employees 15
Crinetics Pharmaceuticals Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Financial Announcements 17
Aug 30, 2018: Crinetics Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 17
Corporate Communications 18
Jun 18, 2018: Crinetics Pharmaceuticals Names Alan Krasner As Chief Medical Officer 18
Jan 04, 2018: Crinetics Pharmaceuticals Appoints Marc Wilson as Chief Financial Officer 19
Government and Public Interest 20
Apr 28, 2018: Crinetics Pharmaceuticals Awarded NIH Phase-I SBIR Grant to Develop Somatostatin Receptor Agonist Drugs for Ophthalmic Diseases 20
Product News 21
07/13/2017: Crinetics Pharmaceuticals Awarded $2.8 Million SBIR Grant to Support Development of Acromegaly Drug Candidate CRN00808 21
06/21/2018: Crinetics Pharmaceuticals Awarded up to $3.2 Million in SBIR Grants for Acromegaly 22
03/12/2018: Crinetics Pharmaceuticals Announces Presentation on Hyperinsulinemia Drug Candidate at ENDO 2018 23
Clinical Trials 24
Mar 12, 2018: Crinetics Pharmaceuticals Announces Upcoming Presentation on Acromegaly Drug Candiadate CRN00808 at ENDO 2018 24
Oct 26, 2017: Crinetics Pharmaceuticals Initiates Phase 1 Study of Lead Candidate CRN00808 for Acromegaly 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crinetics Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Crinetics Pharma Raises USD63.5 Million in Series B Financing 10
Crinetics Pharma Raises USD40 Million in Series A Financing Round 12
Crinetics Pharma Raises USD117.3 Million in IPO of Shares 13
Crinetics Pharmaceuticals Inc, Key Competitors 14
Crinetics Pharmaceuticals Inc, Key Employees 15

List of Figures
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Crinetics Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Crinetics Pharmaceuticals Inc (CRNX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • UPM-Kymmene Corporation:企業の戦略・SWOT・財務情報
    UPM-Kymmene Corporation - Strategy, SWOT and Corporate Finance Report Summary UPM-Kymmene Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • CEWE Stiftung & Co.KGaA (CWC):企業の財務・戦略的SWOT分析
    CEWE Stiftung & Co.KGaA (CWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • City Developments Ltd:企業の戦略・SWOT・財務情報
    City Developments Ltd - Strategy, SWOT and Corporate Finance Report Summary City Developments Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Globo Comunicacao e Participacoes S.A.:企業の戦略的SWOT分析
    Globo Comunicacao e Participacoes S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Capri Holdings Ltd:企業の戦略・SWOT・財務分析
    Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Capri Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Gilead Sciences, Inc.:戦略・SWOT・企業財務分析
    Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gilead Sciences, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Prescient Therapeutics Ltd (PTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a clinical stage oncology company that develops novel drugs for the treatment of solid and hematological cancers. The company’s lead drug candidate includes PTX-200, a potent small molecule inhibitor of the …
  • DiaGenic ASA (NEL)-医療機器分野:企業M&A・提携分析
    Summary DiaGenic ASA (DiaGenic) is a medical device company that develops innovative in vitro diagnostic products for early detection of diseases. The company specializes in developing blood-based biomarkers. Its ADtect product is a blood test that helps distinguish mild to moderate range AD from th …
  • Ablynx NV (ABLX)-製薬・医療分野:企業M&A・提携分析
    Summary Ablynx NV (Ablynx) is a clinical-stage biopharmaceutical company focused on the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are a novel class of antibody-derived therapeutic proteins which possess structural and functional …
  • Patrick Industries Inc:企業のM&A・事業提携・投資動向
    Patrick Industries Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Patrick Industries Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Kuwait Projects Company Holding KSC (KPROJ):企業の財務・戦略的SWOT分析
    Kuwait Projects Company Holding KSC (KPROJ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • CIMIC Group Limited:企業のM&A・事業提携・投資動向
    CIMIC Group Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CIMIC Group Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • FlightSafety International Inc:企業の戦略・SWOT・財務情報
    FlightSafety International Inc - Strategy, SWOT and Corporate Finance Report Summary FlightSafety International Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Atomenergoprom:企業の戦略的SWOT分析
    Atomenergoprom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Vericel Corp (VCEL):医療機器:M&Aディール及び事業提携情報
    Summary Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn domains. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts fo …
  • Sir Robert McAlpine Ltd:企業の戦略的SWOT分析
    Sir Robert McAlpine Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • SSE Plc (SSE):石油・ガス:M&Aディール及び事業提携情報
    Summary SSE Plc (SSE) is an integrated energy utility. It develops, owns and operates energy and related infrastructure and services. The company generates, transmits, distributes, and supplies electricity; and produces, stores, distributes, and supplies gas. SSE produces electricity in gas- and oil …
  • Parkway Properties Inc:企業のM&A・事業提携・投資動向
    Parkway Properties Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Parkway Properties Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Cochin Shipyard Ltd (COCHINSHIP):企業の財務・戦略的SWOT分析
    Cochin Shipyard Ltd (COCHINSHIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Xped Ltd (XPE):企業の財務・戦略的SWOT分析
    Xped Ltd (XPE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆